The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
History of Oncolytic Viruses: Genesis to Genetic Engineering
Open accessAbstract
Since the turn of the nineteenth century, when their existence was first recognized, viruses have attracted considerable interest as possible agents of tumor destruction. Early case reports emphasized regression of cancers during naturally acquired virus infections, providing the basis for clinical trials where body fluids containing human or animal viruses were used to transmit infections to cancer patients. Most often the viruses were arrested by the host immune system and failed to impact tumor growth, but sometimes, in immunosuppressed patients, infection persisted and tumors regressed, although morbidity as a result of the infection of normal tissues was unacceptable. With the advent of rodent models and new methods for virus propagation, there were numerous attempts through the 1950s and 1960s to force the evolution of viruses with greater tumor specificity, but success was limited and many researchers abandoned the field. Technology employing reverse genetics later brought about a renewal of interest in virotherapy that allowed the generation of more potent, tumor-specific oncolytics. Here, examination of early oncolytic virotherapy before genetic engineering serves to highlight tremendous advances, yet also hints at ways to penetrate host immune defenses, a significant remaining challenge in modern virotherapy research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Viral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of RNA Tumour Viruses
BALTIMORE, D. (1970) · Nature · doi:10.1038/2261209a0 · Cited by 2,068
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806
Three-Dimensional Structure of Poliovirus at 2.9 Å Resolution
Hogle, J. M., Chow, M., & Filman, D. J. (1985) · Science · doi:10.1126/science.2994218 · Cited by 1,260
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
(1952) · Cancer Research · Cited by 987
Edward Jenner and the History of Smallpox and Vaccination
Riedel, S. (2005) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2005.11928028 · Cited by 964
Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 815
Cloned Poliovirus Complementary DNA Is Infectious in Mammalian Cells
Racaniello, V. R., & Baltimore, D. (1981) · Science · doi:10.1126/science.6272391 · Cited by 696
Radiation oncology: a century of achievements
Bernier, J., Hall, E. J., & Giaccia, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1451 · Cited by 628
The Growth in Vitro of Single Isolated Tissue Cells
(1948) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/9.3.229 · Cited by 588
Cited by
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Self-citationOncolytic virus therapy: A new era of cancer treatment at dawn
Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 774
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Oncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 459
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Cattaneo, R., Miest, T., Shashkova, E. V., & Barry, M. A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1927 · Cited by 373
Oncolytic viruses for cancer immunotherapy
Hemminki, O., dos Santos, J. M., & Hemminki, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00922-1 · Cited by 351
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Kim, T. K., Vandsemb, E. N., Herbst, R. S., & Chen, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00493-5 · Cited by 351
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Yang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 293
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Oncolytic Newcastle Disease Virus for Cancer Therapy: Old Challenges and New Directions
Zamarin, D., & Palese, P. (2012) · Future Microbiology · doi:10.2217/fmb.12.4 · Cited by 254
Assessing the future of solid tumor immunotherapy
Guha, P., Heatherton, K. R., O’Connell, K. P., Alexander, I. S., & Katz, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030655 · Cited by 105
Engineered Bacteriophage T7 as a Potent Anticancer Agent in vivo
Hwang, Y. J., & Myung, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.491001 · Cited by 31
Yaacov, B., Lazar, I., Tayeb, S., Frank, S., Izhar, U., Lotem, M., Perlman, R., Ben-Yehuda, D., Zakay-Rones, Z., & Panet, A. (2012) · Journal of General Virology · doi:10.1099/vir.0.043281-0 · Cited by 29
New role of bacteriophages in medical oncology
Moradi, M., Ghaleh, H. E. G., Bolandian, M., & Dorostkar, R. (2023) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2506 · Cited by 2
Metadata
- Authors
- Kelly, E., & Russell, S. J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2007-04
- Volume
- 15
- Issue
- 4
- Pages
- 651-659
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2063512646
- Cited by
- 763
- References
- 58
- FWCI
- 13.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.